Research ExplorerPublicationsLow-dose thalidomide and donor lymphocyte infusion as adopti...

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

Standard

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. / Kröger, Nicolaus-Martin; Shimoni, Avichai; Zagrivnaja, Maria; Ayuketang Ayuk, Francis; Lioznov, Michael; Schieder, Heike; Renges, Helmut-Hans; Fehse, Boris; Zabelina, Tatjana; Nagler, Arnon; Zander, Axel.

In: BLOOD, Vol. 104, No. 10, 10, 2004, p. 3361-3363.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N-M, Shimoni, A, Zagrivnaja, M, Ayuketang Ayuk, F, Lioznov, M, Schieder, H, Renges, H-H, Fehse, B, Zabelina, T, Nagler, A & Zander, A 2004, 'Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.', BLOOD, vol. 104, no. 10, 10, pp. 3361-3363. <http://www.ncbi.nlm.nih.gov/pubmed/15292062?dopt=Citation>

APA

Kröger, N-M., Shimoni, A., Zagrivnaja, M., Ayuketang Ayuk, F., Lioznov, M., Schieder, H., Renges, H-H., Fehse, B., Zabelina, T., Nagler, A., & Zander, A. (2004). Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. BLOOD, 104(10), 3361-3363. [10]. http://www.ncbi.nlm.nih.gov/pubmed/15292062?dopt=Citation

Vancouver

Kröger N-M, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. BLOOD. 2004;104(10):3361-3363. 10.

Bibtex

@article{029473e3e0da48a2876df0b94d33ff9f,
title = "Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.",
abstract = "To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.",
author = "Nicolaus-Martin Kr{\"o}ger and Avichai Shimoni and Maria Zagrivnaja and {Ayuketang Ayuk}, Francis and Michael Lioznov and Heike Schieder and Helmut-Hans Renges and Boris Fehse and Tatjana Zabelina and Arnon Nagler and Axel Zander",
year = "2004",
language = "Deutsch",
volume = "104",
pages = "3361--3363",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

RIS

TY - JOUR

T1 - Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

AU - Kröger, Nicolaus-Martin

AU - Shimoni, Avichai

AU - Zagrivnaja, Maria

AU - Ayuketang Ayuk, Francis

AU - Lioznov, Michael

AU - Schieder, Heike

AU - Renges, Helmut-Hans

AU - Fehse, Boris

AU - Zabelina, Tatjana

AU - Nagler, Arnon

AU - Zander, Axel

PY - 2004

Y1 - 2004

N2 - To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.

AB - To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.

M3 - SCORING: Zeitschriftenaufsatz

VL - 104

SP - 3361

EP - 3363

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 10

M1 - 10

ER -